Dana P. Goldman, PhD

Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

An analysis of claims from over 90,000 patients with type 2 diabetes (T2D) demonstrates that increased medication cost sharing is associated with higher rates of hospitalization and increased plan costs.

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.

This study examines the association between plan-level measures of health outcomes and medication adherence to assess the viability of adherence as a measure of plan performance.

This study examined the impact of the Medicare Part D coverage gap on medication use by Hispanics, blacks, and whites with diabetes.

This study measures the impact of Medicaid formulary restrictions on the rate at which patients who failed on a drug therapy for schizophrenia return to the same therapy.

Retrospective analysis of medical and pharmacy claims for patients diagnosed with schizophrenia or bipolar disorder in 24 state Medicaid programs.

Instrumental variables regression analysis indicated that inpatient oral nutritional supplement use decreased length of stay, episode cost, and 30-day readmission probability.

Across the US, adults with major medical conditions were less likely to die in hospitals with higher spending levels, even after adjusting for patient risk.

Physicians prescribe more broadly than commonly perceived. Although most physicians have a favorite drug, they are not reluctant to try new therapies.

Coverage under Part D is comparable to that under non–Part D plans with respect to key features likely to be important to Medicare beneficiaries.

Biologic therapy for rheumatoid arthritis or multiple sclerosis was associated with lower use of some types of medical services within 2 to 3 years of initiation.